4//SEC Filing
Cross Shawn 4
Accession 0001437749-23-035527
CIK 0000922247other
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 9:50 PM ET
Size
7.7 KB
Accession
0001437749-23-035527
Insider Transaction Report
Form 4
Cross Shawn
Director
Transactions
- Award
Common Stock
2023-12-27+72,606→ 72,606 total - Award
Stock Option (Right to buy)
2023-12-27+88,910→ 89,910 totalExercise: $2.96From: 2023-12-27Exp: 2024-12-27→ Common Stock (88,910 underlying)
Footnotes (2)
- [F1]On September 21, 2023, Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. ("Merger Sub"), and Applied Molecular Transport, Inc. ("AMTI") entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into AMTI, with AMTI continuing as a wholly owned subsidiary of Cyclo and the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger on December 27, 2023, the Reporting Person received shares of Cyclo common stock in exchange for shares of AMTI common stock and options to acquire shares of Cyclo common stock in exchange for options to acquire shares of AMTI common stock, each based on the exchange ratio determined by the Merger Agreement. All AMTI restricted stock units held by the Reporting Person were fully settled prior to the effective time of the Merger.
- [F2]The options were fully vested upon the closing of the Merger Agreement.
Documents
Issuer
Cyclo Therapeutics, Inc.
CIK 0000922247
Entity typeother
Related Parties
1- filerCIK 0001734779
Filing Metadata
- Form type
- 4
- Filed
- Dec 27, 7:00 PM ET
- Accepted
- Dec 28, 9:50 PM ET
- Size
- 7.7 KB